Wedbush upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $36.00 (from $14.00), as FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE